BACKGROUND/AIMS: Retinoid X receptor alpha (RXRalpha), the heterodimeric partner for multiple nuclear receptors (NRs), was shown to be an essential target for inflammation-induced cJun-N-terminal kinase (JNK) signaling in vitro. This study aimed to explore the role of hepatic JNK signaling and its effects on nuclear RXRalpha levels downstream of interleukin-1beta (IL-1beta) in vivo. METHODS: Effects of IL-1beta on hepatic NR-dependent gene expression, nuclear RXRalpha levels, and roles for individual JNK isoforms were studied in wild-type, Jnk1(-/-), and Jnk2(-/-) mice and in primary hepatocytes of each genotype. RESULTS: IL-1beta administration showed a time-dependent reduction in expression of the hepatic NR-dependent genes Ntcp, Cyp7a1, Cyp8b1, Abcg5, Mrp2, and Mrp3. IL-1beta treatment for 1h activated JNK and resulted in both post-translational modification and reduction of nuclear RXRalpha. In wild-type primary hepatocytes, IL-1beta modified and reduced nuclear RXRalpha levels time dependently, which was prevented by chemical inhibition of JNK as well as by inhibition of proteasomal degradation. Individual absence of either JNK1 or JNK2 did not significantly influence the reduction or modification of hepatic nuclear RXRalpha by IL-1beta both in vivo and in primary hepatocytes. CONCLUSIONS: Functional redundancy exists for JNK1 and JNK2 in IL-1beta-mediated alterations of hepatic nuclear RXRalpha levels, stressing the importance of this pathway in mediating the hepatic response to inflammation.
BACKGROUND/AIMS: Retinoid X receptor alpha (RXRalpha), the heterodimeric partner for multiple nuclear receptors (NRs), was shown to be an essential target for inflammation-induced cJun-N-terminal kinase (JNK) signaling in vitro. This study aimed to explore the role of hepatic JNK signaling and its effects on nuclear RXRalpha levels downstream of interleukin-1beta (IL-1beta) in vivo. METHODS: Effects of IL-1beta on hepatic NR-dependent gene expression, nuclear RXRalpha levels, and roles for individual JNK isoforms were studied in wild-type, Jnk1(-/-), and Jnk2(-/-) mice and in primary hepatocytes of each genotype. RESULTS:IL-1beta administration showed a time-dependent reduction in expression of the hepatic NR-dependent genes Ntcp, Cyp7a1, Cyp8b1, Abcg5, Mrp2, and Mrp3. IL-1beta treatment for 1h activated JNK and resulted in both post-translational modification and reduction of nuclear RXRalpha. In wild-type primary hepatocytes, IL-1beta modified and reduced nuclear RXRalpha levels time dependently, which was prevented by chemical inhibition of JNK as well as by inhibition of proteasomal degradation. Individual absence of either JNK1 or JNK2 did not significantly influence the reduction or modification of hepatic nuclear RXRalpha by IL-1beta both in vivo and in primary hepatocytes. CONCLUSIONS: Functional redundancy exists for JNK1 and JNK2 in IL-1beta-mediated alterations of hepatic nuclear RXRalpha levels, stressing the importance of this pathway in mediating the hepatic response to inflammation.
Authors: L A Denson; E Sturm; W Echevarria; T L Zimmerman; M Makishima; D J Mangelsdorf; S J Karpen Journal: Gastroenterology Date: 2001-07 Impact factor: 22.682
Authors: K Sabapathy; Y Hu; T Kallunki; M Schreiber; J P David; W Jochum; E F Wagner; M Karin Journal: Curr Biol Date: 1999-02-11 Impact factor: 10.834
Authors: Michael Macoritto; Loan Nguyen-Yamamoto; Dao Chao Huang; Sara Samuel; Xian Fang Yang; Tian Tian Wang; John H White; Richard Kremer Journal: J Biol Chem Date: 2007-11-14 Impact factor: 5.157
Authors: Nathalie Arbour; Denise Naniche; Dirk Homann; Roger J Davis; Richard A Flavell; Michael B A Oldstone Journal: J Exp Med Date: 2002-04-01 Impact factor: 14.307
Authors: Anuradha Rao; Astrid Kosters; Jamie E Mells; Wujuan Zhang; Kenneth D R Setchell; Angelica M Amanso; Grace M Wynn; Tianlei Xu; Brad T Keller; Hong Yin; Sophia Banton; Dean P Jones; Hao Wu; Paul A Dawson; Saul J Karpen Journal: Sci Transl Med Date: 2016-09-21 Impact factor: 17.956
Authors: Sylvie M Mimche; Beatrice A Nyagode; Matthew D Merrell; Choon-Myung Lee; Nina S Prasanphanich; Richard D Cummings; Edward T Morgan Journal: Drug Metab Dispos Date: 2013-10-25 Impact factor: 3.922